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Abstract 
The morbidity and mortality from coronary artery disease (CAD) remain significant worldwide. 
The treatment for acute myocardial infarction has improved over the past decades, including early 
reperfusion of culprit coronary arteries. Although it is mandatory to reperfuse the ischaemic 
territory as soon as possible, paradoxically this leads to additional myocardial injury, namely 
ischaemia/reperfusion (I/R) injury, in which redox stress plays a pivotal role and for which no 
effective therapy is currently available. In this review, we report evidence that the redox 
environment plays a pivotal role not only in I/R injury but also in cardioprotection. In fact, 
cardioprotective strategies, such as pre- and post-conditioning, result in a robust reduction in infarct 
size in animals and the role of redox signalling is of paramount importance in these conditioning 
strategies. Nitrosative signalling and cysteine redox modifications, such as S-nitrosation/S-
nitrosylation, are also emerging as very important mechanisms in conditioning cardioprotection. 
The reasons for the switch from protective oxidative/nitrosative signalling to deleterious 
oxidative/nitrosative/nitrative stress are not fully understood. The complex regulation of this switch 
is, at least in part, responsible for the diminished or lack of cardioprotection induced by 
conditioning protocols observed in ageing animals and with co-morbidities as well as in humans. 
Therefore, it is important to understand at a mechanistic level the reasons for these differences 
before proposing a safe and useful transition of ischaemic or pharmacological conditioning. Indeed, 
more mechanistic novel therapeutic strategies are required to protect the heart from I/R injury and 
to improve clinical outcomes in patients with CAD.  
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Introduction 
The prevalence of chronic and degenerative diseases, including cardiovascular disease (CVD), is 
increasing worldwide. Acute coronary syndromes, including myocardial infarction, are the most 
typical examples of pathologies with a strong redox-sensitive component and remain the leading 
cause of death in Western countries despite significant progress in primary and secondary 
prevention and treatment strategies. The only way to treat acute myocardial infarction (AMI) is to 
promptly restore blood flow to the ischaemic tissue. However, reperfusion is associated with further 
injury and the duration of the precedent ischaemia is an important determinant of the extent of 
reperfusion damage (Ferdinandy and Schulz, 2003; Hoffman et al., 2004). Reactive oxygen 
species/reactive nitrogen species (ROS/RNS) production, which may continue for hours after the 
beginning of reperfusion, plays an important role in the genesis of reperfusion injury (Bolli et al., 
1989) and recruitment of inflammatory cells (Simoons et al., 1986). This is known as 
ischaemia/reperfusion (I/R) injury (Penna et al., 2009; Pagliaro et al., 2011; Perrelli et al., 2011; 
Tullio et al., 2013). Oxidative and nitrosative/nitrative stress contribute to the cascade of events 
leading to cell death in acute coronary syndrome, and increased production of ROS/RNS can 
modify the expression of several inflammatory mediators during heart injury. Here, we use the word 
‘stress’ with a negative connotation, as it will lead to tissue damage. This is somewhat different 
from the chemical terminology (see Heinrich et al., 2013). When ROS/RNS are protective or 
involved in physiological mechanisms, we speak of ‘redox signalling’ (see below). In coronary 
disease, inflammatory processes are involved in a vicious cycle of deleterious events that lead to 
cardiac damage, including further oxidative stress, impairing both diastolic and systolic function 
(Toyokuni, 1999). Thus, not only ischaemic damage, but also reperfusion, can produce cardiac 
injury and dysfunction. Moreover, I/R injury alters cell excitability and their conduction system, 
leading to arrhythmias via several mechanisms (Majidi et al., 2009; Lopes et al., 2012). Reperfusion 
also damages the vascular endothelium, leading to changes in the endothelial structure (e.g. 
expression of molecules of adhesion) and alignment, with capillary leakage and alterations in blood 
cells and microembolization, as well as vascular compression due to myocyte swelling. There is no 
doubt that acute coronary syndrome and redox biology are entangled and concomitant diseases 
(comorbidities), making the condition more complicated. Ageing is a powerful predictor of adverse 
events following coronary syndrome and reperfusion strategies (Eagle et al., 2004; Schröder et al., 
2013). Moreover, it is not clear why older patients continue to have poor outcomes in this syndrome 
despite improved access to contemporary treatment (Gale et al., 2012). One of the reasons may be 
the exacerbation of redox-dependent reperfusion injury in these conditions and in the presence of 
co-morbidities, such as metabolic syndrome, diabetes and cardiac hypertrophy (Giricz et al., 2006; 
2009; Ferdinandy et al., 2007; Görbe et al., 2011; Kocsis et al., 2012; Csonka et al., 2014). Besides 
increasing ROS/RNS production, ischaemia and reperfusion have also been found to reduce the 
levels of antioxidant enzymes such as glutathione peroxidase, and superoxide dismutase (SOD) and 
non-enzymatic antioxidant such as ascorbate and GSH (Vaage et al., 1997). Moreover, I/R alters the 
function of several enzymes, some of which play an important role in the redox balance of the cell 
(Penna et al., 2011b; Tullio et al., 2013). Therefore, reduced scavenging and altered enzymatic 
function further contribute to the development of oxidative stress. Many hopes were pinned on the 
use of antioxidants, but results have been disappointing, so far (see the Bench to bedside section). 
Therefore, there is an urgent need to better understand the biology and the damage caused by I/R 
and redox stress before considering an appropriate treatment. Clearly, the same level of 
radical/reactive species may be protective or deleterious, depending on a variety of conditions, 
including co-morbidities, the protective antioxidant enzyme defence system and reparative process. 
I/R damage can be reduced by ischaemic preconditioning (I-PreC) (Hoffman et al., 2004; 
Hausenloy and Yellon, 2007; Hausenloy et al., 2007; 2013; Murphy and Steenbergen, 2008; Di Lisa 
et al., 2011) and by ischaemic postconditioning (I-PostC) (Hausenloy and Yellon, 2007; 2008; 
Hausenloy et al., 2007; 2013; Ivanes et al., 2011; Pagliaro et al., 2011). The mechanisms underlying 
protection by I-PreC and I-PostC are incompletely understood (Penna et al., 2008a; 2009; Di Lisa et 
al., 2011; Pagliaro et al., 2011; Perrelli et al., 2011; Tullio et al., 2013). However, there are no 
doubts that ROS/RNS signalling plays a role in triggering and mediating these protective 
phenomena. It is likely that mitochondria have an important role in these processes. For instance, 
autacoids, formed during conditioning manoeuvres, can trigger protection by inducing activation of 
the mitochondrial K+ ATP channel (mitoKATP), which then induces the generation of ROS and 
RNS, both required for conditioning-induced protection (O’Rourke, 2000; Cohen et al., 2001; 
Forbes et al., 2001; Oldenburg et al., 2002; 2004; Gucek and Murphy, 2010; Di Lisa et al., 2011; 
Murphy et al., 2012; 2014; Penna et al., 2013a) (Figure 1). Notably, I-PreC can be mimicked by 
pharmacological interventions, including the administration of free radical donors/generators, NO 
donors, and even nitroxyl anion (HNO/NO−) and ONOO− donors (Wink et al., 1993; Pagliaro, 
2003; Pagliaro et al., 2003; du Toit et al., 2008; Tocchetti et al., 2011), whereas pre- and post-
conditioning can be blocked by radical scavengers (Penna et al., 2006b; Cohen et al., 2008). 
Although the cardioprotective effect of conditioning strategies have been proven in several species 
including humans, it seems that the presence of cardiovascular risk factors, ageing, co-morbidities 
and other concomitant medications may interfere with cardioprotective signalling pathways (for 
extensive reviews, see Ferdinandy et al., 2007; Ovize et al., 2013; Hausenloy et al., 2013). 
Therefore, there is a complex framework in which ROS/RNS can be deleterious (redox stress) or 
beneficial (redox signalling); a picture that is further complicated by the presence of co-morbidities. 
In this review, we will first consider the molecular basis of ROS/RNS generation and the 
mechanisms of oxidative and nitrosative/nitrative stress. Then, we will consider how ROS/ RNS 
may have a physiological/beneficial role (ROS/RNS signalling) and how ROS/RNS are involved in 
the process of cardioprotection, namely pre- and post-conditioning. Finally, the possibilities of 
clinical transition of the conditioning protocols are discussed.  
 
Molecular basis of the biologicalfunction of ROS/RNS 
The cellular redox status may be considered a continuum that ranges from reductive to oxidative 
conditions. Reactive species overflow can occur at either extreme (i.e. oxidized or reduced) of the 
redox potential. Therefore, the biological extremes of the redox spectrum play pivotal roles in 
disease pathogenesis. Here, we consider oxidative stress and signalling; for reductive stress (i.e. 
increased ratios of NADPH/ NADP and GSH/GSSG), see the review of Brewer et al. (2013). We 
propose to revise our approach towards the redox balance and to consider the production of ROS 
and RNS as a physiological phenomenon that is involved in the regulation of various cellular 
functions. Only under certain conditions this balanced production can ‘escape’ from the usual 
control and consequently induce damage via oxidative/nitrosative/ nitrative stress. As such, 
oxidative stress and nitrosative/ nitrative stress are disturbances in the oxidation/reduction state of 
the cell, in which inappropriate ROS/RNS production exceeds antioxidant defences. As a rule, 
ROS/RNS activity determines toxicity while decreasing signalling ability. However, exceptions 
exist.  
 
ROS/RNS and oxidative/nitrosative signalling or stress 
The reactive species 
Before considering the sources of ROS/RNS, here we briefly review the biochemistry and biology 
of the reactive species. Although reactions to RNS will be considered in more detail, the reader is 
kindly redirected to more focused reviews on this topic (Espey et al., 2002; Becker, 2004; Martínez 
and Andriantsitohaina, 2009; Heinrich et al., 2013; Penna et al., 2014).  
ROS 
A reduction in molecular oxygen (O2) leads to the formation of chemically reactive species (known 
as ROS). These are the superoxide anion (O2 −), hydrogen peroxide (H2O2) and the hydroxyl 
radical (HO•). Because of their intrinsic chemical properties, each ROS reacts with specific 
biological targets (amino acid and cysteine residues of proteins, lipids, DNA bases, etc.). 
Superoxide anion is a by-product of mitochondrial respiration and is produced mainly by NADPH 
oxidases. In living cells, the steady-state concentration of O2 − is very low (∼10−11 M), which 
reflects its instability; this is due to not only its reaction with the [Fe–S] cluster but also to 
spontaneous and SOD-mediated O2 − dismutation to H2O2. The instability of O2 − and its inability 
to diffuse through membranes because of its negative charge make this ROS a poor signalling 
molecule. However, since O2 − can cross membranes via anion channels, it has often been 
suggested that it is responsible for the cardioprotection triggered in the pre- and postconditioning 
scenario (see below). Hydrogen peroxide is formed as a by-product of aerobic metabolism, 
superoxide formation and dismutation, and as a product of oxidase activity. Both excessive H2O2 
and its decomposition product, HO•, formed in a metal-catalysed Fenton-type reaction, are harmful 
for most cell components. In biological systems, its toxicity is essentially due to its reduction to 
HO• by Fenton chemistry (Imlay, 2003). In fact, H2O2 is a poor oxidant and reacts mildly with 
[Fe–S], loosely binds to metals and very slowly to glutathione, Met and free Cys residues 
(Winterbourn and Metodiewa, 1999). As a consequence, H2O2 is relatively stable (intracellular t1/2 
∼ 1 ms and steady-state levels ∼10−7 M). Since the H2O2 reactivity towards Cys residues can 
increase significantly depending upon the protein environment, the diffusion of H2O2 might be 
modulated by changes in membrane permeability or by transport through aquaporins (Bienert et al., 
2006). Its selective reactivity and diffusibility makes H2O2 the ideal candidate for redox signalling, 
as it reacts selectively throughout the cell. It can act as a second messenger in several signal 
transduction pathways, including immune cell activation, inflammation processes and cell 
proliferation. It has been suggested that H2O2 is a coronary metabolic dilator and couples 
myocardial oxygen consumption to coronary blood flow. It produces vasodilatation by the oxidation 
of intracellular thiols and activation of the p38 MAP kinase. Therefore, physiological coronary 
metabolic dilatation appears to be mediated by redox-dependent signals (Saitoh et al., 2007). The 
reactivity of the hydroxyl radical is mainly nonspecific (t1/2 ∼ 10−9 s), which makes it highly toxic 
and limits its diffusion to sites of production; despite this, HO• may operate in H2O2 sensing 
(Halliwell and Gutteridge, 1997). Thus, it is possible that HO• has cardioprotective properties, as its 
effects may be carried downstream by a product of phospholipid oxidation (Garlid et al., 2013). 
RNS: nitration, glutathionylation and nitrosylation 
RNS are a family of molecules mainly derived from NO, oxygen and superoxide (Figure 2). Nitric 
oxide (nitrogen monoxide, •NO) is synthesized by various NOS enzymes or can be produced by 
other reactions in the biological systems, which are collectively called ‘non- NOS’ processes 
(Zweier et al., 2010). Besides endothelial NOS (eNOS or NOS3), many cells constitutively express 
neuronal NOS (nNOS or NOS1). These two NOSs are Ca2+/calmodulincontrolled isoenzymes, and 
within the organ and cells, they are localized to different microdomains and are linked to selective 
signalling (Lim et al., 2008; Zhang and Casadei, 2012). The localization of enzymes and/or 
antioxidants within the intracellular organelles in the various microdomains has a critical role in the 
redox biology, determining the final outcome of a nitrosative process. Cells can also express an 
inducible NOS (iNOS or NOS2), which can produce a large amount of •NO in immune and 
pathological processes independently of the level of Ca2+ in the cell. Nevertheless, the so-called 
second window of protection of I-PreC is mediated by increased iNOS activity and the role of iNOS 
in I/R injury and, specifically, whether this enzyme is protective or detrimental is still a matter of 
debate. It is likely that iNOS is protective in myocytes but detrimental in inflammatory cells (Guo et 
al., 2005; 2012). Although the three isoforms of NOS catalyse the same reactions, they differ in 
their expression, regulation and physiological/pathophysiological roles (Nathan and Xie, 1994). The 
non-NOS process of •NO formation includes nonenzymatic reactions that are favoured by acidic 
conditions, such as the reduction of nitrite to •NO, and reactions catalysed by non-NOS enzymes, 
such as cytochrome c, Hb and xanthine oxidoreductase (Zweier et al., 2010). Molecular targets of 
•NO include metalloenzymes (especially sGC, Hb and cytochromes) and thiols yielding S-
nitrosothiols (see also below) (Ferdinandy and Schulz, 2003; Pacher et al., 2007; Penna et al., 
2014). The major biological reaction of •NO includes oxidation to nitrite and nitrate. Notably, •NO 
can react with O2 −, yielding peroxynitrite (ONOO−) (Ronson et al., 1999). This reaction leading to 
peroxynitrite formation depletes the bioactivity of •NO (Guzik et al., 2002). This is important 
because •NO is a key mediator in many important physiological and cardiovascular functions, 
including regulation of smooth muscle tone and BP, platelet activation and vascular cell signalling. 
Therefore, although ONOO− itself is a highly reactive species that can react with various biological 
targets of the cell including amino acids, DNA, lipids, thiols and low-molecular-weight antioxidants 
(Pehar et al., 2006), the toxicity of this reaction may be derived from •NO removal. Moreover, this 
reaction occurs at a relatively slow rate and allows ONOO− to act as a signalling molecule. In fact, 
ONOO−, similar to O2 −, is also able to traverse the cell membranes to some extent through anion 
channels (Pacher et al., 2007). Yet, peroxynitrite can react with other molecules to form additional 
types of RNS including nitrogen dioxide (•NO2) and dinitrogen trioxide (N2O3), a nitrosating 
agent. In fact, important reactions involving RNS, such as nitrosonium (NO+), •NO2 and N2O3, are 
those leading to S-nitrosothiol production (see below).  
Nitration and nitrosation or nitrosylation 
Although nitrosylation can be defined as the addition of •NO without a change in the formal charge 
of the substrate (metal centre or radical species) and nitrosation as the formation of a covalent bond 
between an NO+ equivalent and a nucleophilic centre (amine or thiol) (Heinrich et al., 2013), 
nitrosation and nitrosylation are often used interchangeably to refer to the same substrate 
modification, in biological literature (Murphy et al., 2012; Penna et al., 2014). Actually, nitrosation 
or nitrosylation of proteins (i.e. the incorporation of NO moieties by covalent bonding to protein 
groups) is chemically possible in the case of cysteine thiols, leading to the formation of S-
nitrosothiol (thionitrite) (Wink et al., 1993; Heinrich et al., 2013). In fact, S-nitrosothiol may be 
obtained either by the reaction of RNS with a thiol (nitrosation of a thiol) or by •NO with an 
oxidized thiol (nitrosylation of a thiyl radical) and can be clearly individuated because of the prefix 
‘S’, referring to the incorporation of the NO moieties to a sulfur atom to form the S–NO bond. Of 
note, cysteine residues of proteins may be either reactive (pKa 4–5) or nonreactive (pKa 8.5) 
(Knock and Ward, 2011; Burgoyne et al., 2012). Therefore, this post-translational modification (S-
nitrosothiol formation) can be due to either a S-nitrosation or S-nitrosylation process, which has 
become popular as protein S-nitrosylation sounds like protein phosphorylation. Indeed, moderate 
and selective S-nitrosothiol production is emerging as a prototype of redox signalling, which, in 
biology, is often referred to as S-nitrosylation (Sun et al., 2006a; 2012; 2013; Sun and Murphy, 
2010; Kohr et al., 2011; Angelone et al., 2012; Murphy et al., 2012; 2014; Penna et al., 2014) and 
S-nitrosation (Galkin and Moncada, 2007; Nadtochiy et al., 2007; Chouchani et al., 2010; 2013; 
Methner et al., 2013), without any clear evidence that the process leading to S-nitrosothiol 
production is the former or the latter. Therefore, due the consolidate use of these terms (S-
nitrosation/S-nitrosylation), from here on, we will use both terms to refer to the process leading to 
the formation of S-nitrosothiols within proteins, which are often, although inappropriately, referred 
to as S-nitrosylated proteins (for the appropriate chemical terminology in this field, see Heinrich et 
al., 2013). In contrast, nitration involves an electrophilic addition of a nitro triatomic group, such as 
an NO2 + equivalent (nitronium, an electron acceptor), to an aromatic ring (the site of electron 
density) (Espey et al., 2002). In the biological system, the term nitration refers mainly to the 
incorporation of the NO2 + equivalent at position 3 of the phenolic ring of tyrosine residues (3-
nitration of tyrosine or 3-NT). This protein modification is often associated with oxidative/nitrative 
stress, due to the formation of ONOO−, in the pathology of the CVS (Turko and Murad, 2002; 
Ischiropoulos, 2003). However, it must be stressed that, although nitration, nitrosation and 
nitrosylation, are different types of reactions, they are not mutually exclusive events but are related 
in a continuum or Yin-Yang process and in many circumstances can result in identical final 
products (Wink et al., 1993; Penna et al., 2014). For instance, even ONOO− can lead to facilitation 
of the nitrosylation pathway; indeed, it has been suggested that only when the ratio between •NO 
and O2 − is close to 1:1 the formation of ONOO− can lead to nitration, whereas a small excess of 
•NO will predominantly lead to nitrosylation via N2O3 formation (Espey et al., 2002). Actually, S-
nitrosothiol-mediated protection, through both nitrosation- and nitrosylation-dependent 
mechanisms, is influenced by the relative rates of •NO and O2 − formation. Nevertheless, it has 
been suggested that 3-NT formation is one of the steps in protective pathways (Kupai et al., 2009; 
Li et al., 2013). Glutathionylation is the enzyme-independent addition of GSH, or other low-
molecular-weight thiols, to cysteine sulfhydryl residues of proteins. This is a reaction in dynamic 
equilibrium with S-nitrosation/S-nitrosylation of GSH to form S-nitrosoglutathione and is 
considered a cellular response to protect essential proteins from permanent loss of function as a 
consequence of oxidative stress by other ROS/ RNS (Klatt and Lamas, 2000; Heinrich et al., 2013). 
Therefore, RNS have multiple effects on their potential cellular targets, which include not only 
proteins but also lipids and DNA and it is likely that RNS have important effects on the shift from a 
healthy to a disease state (Martínez and Andriantsitohaina, 2009). Indeed, RNS may induce either 
nitrosative stress via the uncontrolled nitrosation of cysteine residues or nitrative stress through the 
irreversible nitration of biological molecules, such as tyrosine. Yet, the most important downstream 
signalling pathway for RNS for conditioning cardioprotection probably involves discrete S-
nitrosation/ S-nitrosylation of proteins and may be partially independent of NO-mediated cGMP 
signalling (Penna et al., 2006a; 2011b; Inserte et al., 2013; Murphy et al., 2014). Actually, in several 
conditions, the main NO signalling is cGMP-dependent and stems from the activation of sGC due 
to the binding of •NO to the haem group of the enzyme, with consequent production of cGMP. The 
subsequent activation of PKG amplifies the signalling events through protein phosphorylation, 
including inositol-1,4,5-triphosphate receptor-associated cGMP kinase substrate, the regulator of G 
protein signalling and the myosin light-chain phosphatase. This ‘classical’ signalling cascade is 
responsible for the NO-dependent vasodilatation and is regulated at several steps, for example, •NO 
production, reversible binding to sGC, degradation of cGMP by PDE and dephosphorylation of 
downstream targets by phosphatases. A plethora of studies can be found on this classical pathway. 
Here, we focus more on the so-called cGMP-independent NO signalling described earlier. As we 
will see, this signalling is very important in preand post-conditioning.  
Sources of ROS and RNS 
Besides chemical reactions, several enzymes, pathways and/or mechanisms are associated with the 
production of reactive species within cells under physiological and pathological conditions. Among 
these, there are sources of ROS/ RNS, including enzymes of mitochondrial respiration, xanthine 
oxo-reductase (XOR), NADPH oxidases [catalytic subunit of NADPH oxidases (Nox)], and 
coupled and uncoupled NOSs (Figure 3). Other important oxidase pathways include autoxidation of 
catecholamines in I/R injury, and the activation of the lipoxygenase and the cytochrome P450 class 
of enzymes, some of which are present in coronary arteries and myocardium and are known to 
produce superoxide in response to several stimuli, including bradykinin (Buttery et al., 1996). The 
majority of these enzymes only produce ROS after they have been damaged by ROS/RNS, as, for 
example, is the case for uncoupled eNOS and XOR. In contrast, NADPH oxidases produce ROS as 
their primary function. Here, we describe briefly the role of some of these sources. The reader is 
redirected to more focused reviews on this topic (Becker, 2004; Zhang and Gutterman, 2007; Costa 
et al., 2011; Sato et al., 2011; Nickel et al., 2014). Mitochondrial production of ROS is mainly the 
net result of O2 − production at the electron transport chain and their elimination by antioxidative 
enzymes, such as manganese SOD in the mitochondrial matrix or copper/zinc SOD in the 
intermembrane space. The production of O2 − by electron transport chain is profoundly influenced 
by ischaemia and reperfusion and seems exalted by the so-called process of ROS-induced ROS 
release (RIRR) (Tullio et al., 2013; Nickel et al., 2014). Another mitochondrial source of oxidative 
signalling and/or stress is monoamine oxidases (MAOs), which are located in the outer 
mitochondrial membrane. MAO mediates the breakdown of key neurotransmitters, such as 
noradrenaline, adrenaline and dopamine, and, in the process, generates H2O2. The activity of MAO 
is altered in I/R and chronic myocardial disease (Kaludercic et al., 2014). Another mitochondrial 
component that contributes to ROS generation is the p66Shc (for extensive review, see Giorgio et 
al., 2007; Di Lisa et al., 2009a,b). Few studies considered p66Shc in the context of I/R injury. In a 
recent study, the susceptibility to I/R injury was greatly decreased in mice hearts devoid of p66Shc 
along with a marked reduction of oxidative alterations of proteins and lipids (Carpi et al., 2009). 
This study suggested that myocardial injury caused by post-ischaemic reperfusion was greatly 
dependent upon the activity of p66Shc. The role of XOR in I/R injury has been demonstrated in 
several heart models of I/R (Berry and Hare, 2004). In the setting of ischaemia, ATP degradation 
leads to the accumulation of XOR substrates. Moreover, XOR activity is increased after I/R injury. 
Actually, oxidative stress after reperfusion injury is most likely to be attributable to a combination 
of local XOR activity and the effects of neutrophils attracted to the region (Harzand et al., 2012). 
NOS uncoupling induced by oxidative stress results in further oxidative/nitrosative/nitrative stress. 
NOS catalytic activity becomes uncoupled when the coupling between the reductase domain and L-
arginine oxidation at the active site is lost and electron transfer from NADPH through the flavins to 
O2 is not inhibited, resulting, in fact, in the formation of O2 −• and OH•. NOS uncoupling occurs 
under certain conditions, such as scarcity or absence of one or more co-factors (calmodulin, FAD, 
FMN and/or tetrahydrobiopterin), or oxidation of the Zn2+–thiolate centre of the NOS homodimer. 
It seems that supplementation with tetrahydrobiopterin may reverse NOS uncoupling in some 
cardiovascular conditions (Carnicer et al., 2013). NOS activity is also profoundly altered in the 
myocardium after an ischaemic insult (Gonzalez et al., 2009). For instance, after AMI, nNOS 
expression in the heart is increased (Damy et al., 2003). However, more importantly, it seems that 
the subcellular localization of nNOS changes from the sarcoplasmic reticulum to the sarcolemma 
concomitantly with the occurrence of uncoupled NOS activity (Zucchi et al., 2001; Simon et al., 
2014). These changes (translocation and uncoupling) explain the different effects of RNS in the 
post- AMI and failing heart as well as in diabetes-associated myocardial dysfunction (Zhang et al., 
2006). Seven NADPH oxidase family members, which have distinct catalytic subunit (i.e. Nox-1–5 
and Duox1 and 2) and different additional protein subunits, have been described (Bedard and 
Krause, 2007; Santos et al., 2011). The two Nox isoforms that have functional effects in 
cardiomyocytes are Nox2 and Nox4. It seems that Nox4 has a mitochondrial and endoplasmic 
reticulum-related perinuclear location and is a slowly inducible isoform. In fact, Nox4 has a low-
level of constitutive activity that seems to be regulated largely by changes in its expression level. 
Nox2 is located predominantly on the plasma membrane and is normally quiescent, but it is acutely 
activated by various stimuli, including angiotensin II. While Nox2 generates predominantly O2 −, 
Nox4 may generate predominantly H2O2 (Ushio-Fukai, 2009; Ago et al., 2010; Brandes et al., 
2010; Nisimoto et al., 2010). It has been reported that NADPH oxidase subunit expression and 
activity are increased in both cardiomyocytes and endothelial cells in an animal model of pressure-
overload left ventricular hypertrophy (Li et al., 2002). It seems that NADPH oxidase activity is 
increased in many cardiac disease states. For example, the expression of NADPH subunits, 
including Nox2, is increased after AMI in both animal models and humans (Krijnen et al., 2003). 
Using mouse models with selective gain and loss of function for these two Nox isoforms, it has 
been proposed that a very different role is played by each isoform, roles that themselves vary 
depending upon the disease condition. Overall, the downstream effects of Nox2 and Nox4 appear to 
differ, with the former mediating detrimental effects (redox stress), whereas the latter may facilitate 
beneficial processes (redox signalling) such as angiogenesis and adaptive hypertrophy. For 
example, deletion of Nox2 was protective against angiotensin II-induced cardiac fibrosis and 
hypertrophy, whereas deletion of Nox4 was detrimental. However, recent studies suggest that high 
levels of Nox4 may have detrimental effects via shifting from H2O2 to O2 −• production (Bedard 
and Krause, 2007; Nisimoto et al., 2010; Santos et al., 2011; Zhang et al., 2013). The reasons for 
this discrepancy remain to be elucidated and the picture may be more complicated than apparent 
from previous studies. Before considering the role of ROS/RNS in cardioprotection, let us further 
define the concepts of redox signalling and stress in the context of cardioprotection. 
 
Redox signals (ROS/RNS signalling) 
The redox signalling comprises oxidoreductive chemical reactions that alter proteins post-
translationally, thereby creating a coupling between redox balance and cell function. Under normal 
circumstances, ROS/RNS concentrations are tightly controlled by endogenous antioxidants, keeping 
them in the picomolar range (Dröge, 2002). However, most cells have been shown to generate a 
burst of ROS/RNS when stimulated by a plethora of chemicals (e.g. cytokines, angiotensin II, 
diazoxide, endothelin-1, PDGF, PAF) and physical stimuli (i.e. intermittent shear stress, thermic 
variations) (Penna et al., 2011a). Then, the ROS/RNS formed play an important role in cellular 
homeostasis and communication. These transiently increased ROS/RNS act as second messengers 
in signal transduction for cell signalling and cardiovascular homeostasis. As said, S-nitrosation/S-
nitrosylation leading to S-nitrosothiol production is a selective post-translational protein 
modification due to targeting of redox-sensitive cysteine residues within proteins. When ROS/RNS 
are modified, proteins alter their activity, stability, conformation and/or ability to interact with other 
molecules, resulting in modulations of cellular function. In the heart, redoxmodified proteins 
include proteins involved in calcium handling and contractile function [e.g. calcium calmodulin 
kinase II, calcium channels, ryanodine receptor, sarco/ endoplasmatic reticulum calcium ATPase 
(SERCA) and phospholamban] (for review, see Burgoyne et al., 2012; Steinberg, 2013; Tullio et al., 
2013), as well as proteins involved in various signalling pathways and/or transcriptional activities. 
Among these are oxidative/nitrosative modifications of enzymes, such as metalloproteinase (MMP) 
and kinases (i.e. PI3K, AMPK, PKA, PKC and PKG), which may lead to the activation or 
inhibition of the enzyme depending upon the type of reaction and the site of oxidative/nitrosative 
modification (see also Knock andWard, 2011; Burgoyne et al., 2012; Steinberg, 2013; Tullio et al., 
2013). The signal may also be indirect; for instance, the H2O2-mediated activation of AMPK is 
likely mediated via the ROS-induced decrease in the ATP levels. It has also been suggested that 
hypoxic activation of AMPK is dependent upon mitochondrial ROS but independent of an increase 
in the AMP/ATP ratio (Emerling et al., 2009). ROS are also important regulators of PKC by 
reacting with thiol groups associated with the zinc-finger region of the molecule (Korichneva, 
2006). Moreover, an RNS-dependent activation of PKC, via a redox-sensitive S-
nitrosation/Snitrosylation process, occurs within the mitochondria (Sun et al., 2006b; Prime et al., 
2009). The small monomeric G proteins (ras, rac-1 and RhoA), transcription factors (e.g. NF-κB 
and HIF-1) and histone deacetylases are also activated by ROS/RNS (Bonello et al., 2007; Morgan 
and Liu, 2011; Satoh et al., 2011; Surma et al., 2011). Finally, a group of kinases that may be 
directly or indirectly redox-sensitive, but very important in cardiovascular cell signalling, are 
MAPKs (see also below) (Johnson and Lapadat, 2002; Martindale and Holbrook, 2002). Also, 
vasodilatation is, in part, due to a cGMP-independent process of glutathionylation, which protects 
the cells from further oxidative/nitrosative modifications (Sun et al., 2006b). In fact, the inhibitor of 
sGC, ODQ (1H-[1,2,4]oxadiazole[4,3,-α]quinoxaline-1-one), does not prevent several NO-
dependent effects in many tissues (Busse and Fleming, 2006; Sun et al., 2013). Moreover, even 
protein nitration has been suggested to be involved in signalling processes during normal 
physiological mechanisms (Koeck et al., 2005). In fact, tyrosine nitration by ONOO− may affect 
tyrosine phosphorylation and MAPK activity in several cell types, thus affecting essential cellular 
functions (Jope et al., 2000). Therefore, ROS/RNS play a very important role in cell signalling and 
are thus essential for survival of the organism (Dröge, 2002; Fisher, 2009). Of course, we must not 
forget that under pathological conditions and in the presence of co-morbidities, ROS/RNS 
production is unbalanced by cell defences, inducing deleterious effects in a large number of 
pathways involved in cell life. The dual role of ROS/RNS in ‘fine-tuning’ the balance between cell 
death and survival is well illustrated by observations that, during I/R injury, ROS/RNS trigger cell 
death (apoptosis/necrosis), whereas ROS/RNS generated during preconditioning as well as during 
post-conditioning manoeuvres prevent cell death (Becker, 2004; Penna et al., 2009; Pagliaro et al., 
2011; Tullio et al., 2013). ROS/RNS generated during conditioning can up-regulate pathways able 
to prevent cell death (see the ROS/RNS and cardioprotection section).  
Oxidative and nitrosative/nitrative stress in CVD 
As said, redox balance may shift from health (signalling) to disease (stress) in acute events, 
especially if events occur during ageing and degenerative conditions. Here, we consider in brief the 
role of redox stress in CVD and in particular in the I/R injury of the myocardium. The reader is 
kindly redirected to other extensive reviews on this topic (Tocchetti et al., 2011; Zhang et al., 2012; 
Morales et al., 2014). Normal cardiovascular performance requires balancing of many complex 
physiological and biochemical processes, including redox balance. Disturbances of this balance 
may lead to myocardial dysfunction or, alternatively, a disrupted balance may be a secondary result 
of structural heart disease such as AMI or cardiomyopathic processes. Altered signalling systems, in 
turn, contribute to the progression of myocardial dysfunction. Therefore, redox imbalance may be 
the cause of cardiac disease, which, in turn, may exacerbate redox imbalance. In fact, when 
excessively produced, or when endogenous antioxidants are depleted, ROS/RNS can inflict damage 
onto lipids, proteins and DNA. This intracellular reduction– oxidation imbalance, namely 
oxidative/nitrosative/nitrative stress, can subsequently contribute to the development and/or 
progression of CVD, such as atherosclerosis, chronic ischaemic heart disease, cardiomyopathy, 
congestive heart failure, arrhythmias as well as several other degenerative conditions rendering the 
CVS more susceptible to stress by I/R challenging (Lopes et al., 2012; Tullio et al., 2013). 
Importantly, ROS/RNS up-regulation leading to cell death is a wanted effect in cancer prevention. 
I/R injury is the prototypical pathological example of a situation in which ROS/RNS are produced 
in amounts far exceeding those that cells and tissues can handle without damage. Redox stress may 
occur both during ischaemia and reperfusion (Becker, 2004). At the cellular level, ischaemia is 
characterized by a virtual lack of O2 and substrates, and ischaemic cells accumulate metabolites 
such as lactate. Via alterations in pH, Na+ and ATP levels, ischaemia and mainly reperfusion then 
trigger a cascade of events including massive ROS/RNS generation, loss of nucleotide homeostasis 
and disruption of Ca2+ homeostasis. Therefore, ROS/RNS are produced during ischaemia, but 
especially at reperfusion (Becker, 2004). Oxidative/nitrosative/nitrative stress plays an important 
role and contributes to the onset and maintenance of post-ischaemic inflammation. 
Oxidative/nitrosative/nitrative stress after reperfusion injury is most likely attributable to a 
combination of local enzyme activity and the effects of recruited neutrophils (Hoffman et al., 2004; 
Zhao, 2004). Increased formation of ROS/RNS is one of the main factors of reperfusion-induced 
injury. During reperfusion, the O2 − production increases, which, along with other ROS/RNS, 
strongly oxidizes the myocardial fibres, thus favouring cell death (Zhao, 2004). As said, O2 − 
production can be theoretically generated by different enzymatic systems, namely NOX, uncoupled 
NOS, XOR and complexes of the respiratory chain in the mitochondria. Indeed, mitochondria are 
key players in I/R injury: basically, disruption of Ca2+ homeostasis results in mitochondrial Ca2+ 
overload and culminates in the formation of the mitochondrial permeability transition pore (mPTP) 
and the activation of cell death signalling pathways (Murphy and Steenbergen, 2008; Lemasters et 
al., 2009; Tullio et al., 2013). Importantly, mPTP opening at reperfusion is a fundamental step of 
the so-called RIRR that self-sustain ROS and consequently RNS production that inflicts irreversible 
damage to the cells (Tullio et al., 2013). In fact, it has been reported that mPTP is maintained in a 
closed state during ischaemia and that in non-protected (naïve) hearts typically opens at reperfusion 
(Obame et al., 2007; Hausenloy et al., 2009). At the beginning of reperfusion, Ca2+ overload, ROS/ 
RNS stress and pH recovery all occur. These three mechanisms are recognized as potent triggers 
that increase the open probability of the mPTP. The opening of mPTP will lead to RIRR and cell 
death by different mechanisms, including mitochondrial disruption from mitochondrial swelling, 
membrane rupture and/or cytochrome c release, which induces programmed cell death pathways 
(Hausenloy et al., 2009; Martin et al., 2011; Penna et al., 2013a). This is one of the main reasons 
why the restoration of blood flow in the infarctculprit artery may paradoxically result in further 
damage to the myocardium. This reperfusion injury can significantly reduce the beneficial effects of 
reperfusion therapy. Therefore, mPTP inhibition at the time of reperfusion appears fundamental to 
all strategies of cardioprotection thus far envisaged (Tullio et al., 2013). As we will see, S-
nitrosation/SRedox signalling in cardioprotection  nitrosylation of some putative components of 
mPTP reduces the probability of pore formation. 
 
ROS/RNS and cardioprotection 
Different cardioprotective strategies such as ischaemic and pharmacological preconditioning have 
been shown to attenuate mitochondrial dysfunction as evidenced by less mitochondrial Ca2+ 
overload, a better NADH balance and reduced ROS/RNS formation during ischaemia as well as on 
reperfusion (Riess et al., 2002b; 2003; Kevin et al., 2003). Although excessive ROS/RNS formation 
during I/R may contribute to reperfusion injury via nitrative stress by peroxynitrite, ROS/RNS are 
important elements in the triggering signal of I-PreC during preconditioning manoeuvres. The role 
of redox balance in I/R injury and in the cardioprotection induced by preconditioning has been 
extensively reviewed earlier (Cohen et al., 2006; Ferdinandy, 2006; Jones and Bolli, 2006; Tullio et 
al., 2013; Penna et al., 2014). Therefore, here we discuss redox signalling in preconditioning and 
focus on more recent studies and especially the involvement of redox signalling in post-
conditioning, that has not yet been reviewed in the literature. 
Preconditioning 
Cardioprotection by I-PreC is obtained by short periods of ischaemia with intervening short periods 
of reperfusion (a few minutes) prior to an infarcting ischaemia. It requires a complex signalling 
cascade to be triggered, which includes the opening of mitoKATP (O’Rourke, 2000; Cohen et al., 
2001; Oldenburg et al., 2002; 2004; Yue et al., 2002). Intriguingly, preconditioning can be 
completely blocked by free radical scavengers, such as N-acetylcysteine (NAC) or 
mercaptopropionyl glycine (MPG) given during preconditioning manoeuvres (Cohen et al., 2001; 
Forbes et al., 2001). These results confirmed that oxidative/nitrosative signalling is involved in 
triggering the cardioprotection induced by preconditioning. In fact, •NO production by activation of 
different types of NOS and/or by non-NOS processes has been shown to be involved in 
cardioprotection procedures (Bell and Yellon, 2001; Oldenburg et al., 2004; Cohen et al., 2006; 
Shiva et al., 2007; Guo et al., 2008; Zweier et al., 2010; Simon et al., 2014). Even donors of HNO 
(one electron reduction product of •NO) may induce a preconditioning-like effect, which is reversed 
by NAC (Pagliaro et al., 2003). The ‘classical’ protection induced by •NO in I-PreC is dependent, 
in part, upon the activation of sGC/cGMP/PKG, which, in turn, leads to the opening of the 
mitoKATP channel (Jones and Bolli, 2006). Recently, Sun et al. (2013) reported that the I-PreC-
induced cardioprotection is not related primarily to the activation of the sGC/cGMP/PKG signalling 
pathway by •NO, but rather through S-nitrosation/S-nitrosylation signalling. In fact, the infusion of 
the sGC inhibitor, ODQ, did not completely abolish the cardioprotection induced by I-PreC. Hearts 
treated with ODQ were protected with a concomitant higher S-nitrosothiol level. These results 
suggest, at least in some models of cardioprotection, that •NO-mediated cardioprotection is 
regulated by protein S-nitrosation/S-nitrosylation of cysteine residues rather than through activation 
of the sGC/ cGMP/PKG signalling (Sun et al., 2013). The ease of reversibility and the affirmation 
of regulated S-nitrosylating and denitrosylating enzymatic and non-enzymatic reactions support the 
hypothesis that S-nitrosylation regulates the cellular and mitochondrial function through redox 
mechanisms (Penna et al., 2014). Although the majority of authors demonstrate that •NO is 
involved in cardioprotection via cGMPdependent or cGMP-independent mechanisms, others have 
obtained controversial results using inhibitors of NOS (Jones and Bolli, 2006). A great part of 
preconditioning protection is due to the limitation of reperfusion injury with a limitation of 
ROS/RNS stress, mainly due to the prevention of mPTP opening in the early phase of reperfusion 
(Hausenloy et al., 2007; 2009; Hausenloy and Yellon, 2009). The prevention of mPTP opening 
avoids RIRR and redox stress, whereas oxidative/ nitrosative signalling may occur and protect the 
heart. The readers can find several reviews describing the protective role of the reperfusion injury 
salvage kinase (RISK), the survivor activating factor enhancement (SAFE) and the cGMP/PKG 
pathways (e.g. Penna et al., 2008a; 2013a; Boengler et al., 2011; Hausenloy et al., 2011; 2013), 
which comprise phosphorylation of several target proteins. In brief, enzymes that have been shown 
to be involved in these pathways include phosphotidylinositol-3-phosphate kinase, extracellular 
signal-regulated protein kinases, PKB or Akt, PKC, eNOS and JAK-STAT3, a series of kinases that 
have been termed RISK and SAFE pathways. Once the organ has been preconditioned, these 
pathways are re-activated at reperfusion, leading, together with other factors, to the prevention of 
the mPTP formation. The mitochondria in the cell thus continue to be functional and do not release 
pro-apoptotic factors, preventing cell death in reperfusion. However, it is unclear how the heart 
‘remembers’ that it is preconditioned. Similar mechanisms have been observed with regard to I-
PostC, mainly implicating the RISK and SAFE pathways and the prevention of mPTP formation 
(see below). Pharmacological therapy can thus mimic conditioning by targeting the cells at one of 
these points at the level of the receptors, the signal transduction pathways or the mitochondria. 
Here, we focus on recent studies reporting S-nitrosation/ S-nitrosylation of critical proteins as a 
pivotal mechanism of cardioprotection by preconditioning (Murphy and Steenbergen, 2007; Sun et 
al., 2007; 2012). Recently, Kohr et al. (2011), using two different methods to measure protein 
oxidation, showed that preconditioning leads to S-nitrosylation of several proteins and that most of 
these proteins are protected from further oxidation. S-nitrosation/S-nitrosylation of proteins 
involved in calcium handling, such as Ca2+ channels, phospholamban and SERCA2, has been 
demonstrated (Sun et al., 2006a; Sun and Murphy, 2010; Angelone et al., 2012; Murphy et al., 
2014). Moreover, multiple S-nitrosothiol proteins have been shown by proteomic studies in the 
presence of PreC (Arrell et al., 2006; Shi et al., 2008; Foster et al., 2009). In particular, many of 
these proteins have been found within the mitochondria, including proteins responsible for 
mitochondrial metabolism (e.g. αKGDH, glycogen phosphorylase, aconitase). Other important 
mitochondrial components that are subjected to S-nitrosation/S-nitrosylation during the PreC are the 
respiratory complexes, including complex I, which is reversibly inhibited when S-nitrosylated 
(Nadtochiy et al., 2007) or irreversibly inhibited when it is subjected to nitration by ONOO− 
(Galkin and Moncada, 2007; Sun and Murphy, 2010). Another effect usually observed in 
conditioning protection is the inhibition of F0-F1-ATPase. This can occur by S-nitrosation/S-
nitrosylation, with consequent reduction of ATP consumption by the reverse mode of the F0-F1-
ATPase, which typically occurs in I/R of the myocardium (Penna et al., 2004). The inhibition of F0-
F1-ATPase preserves ATP levels and reduces the mitochondrial potential, thereby reducing the 
driving force for Ca2+ uptake into the mitochondria, thus increasing tolerance to I/R (Shiva et al., 
2007). Notably, the inhibition of mPTP opening is regulated by ROS, Ca2+ and mitochondrial 
membrane potential (Heusch et al., 2010; Boengler et al., 2011; Penna et al., 2013a), which are also 
regulated by S-nitrosation/Snitrosylation of critical proteins (Piantadosi, 2012). Not only the 
decrease in Ca2+ loading by increased re-uptake by S-nitrosylated SERCA2, but also the S-
nitrosylation of F0-F1- ATPase, reduces indirectly the opening of mPTP, which reduces the 
breakdown of glycolytic ATP and the acceleration of the fall in the mitochondrial membrane 
potential. Moreover, S-nitrosylation of cyclophilin D (Nguyen et al., 2011) and/or of voltage-
dependent anion channel (Penna et al., 2013a), two putative components of mPTP rich in thiol 
groups, may occur in cardioprotection. All together, these data support the view that S-
nitrosation/S-nitrosylation of mitochondrial and calcium-handling proteins serves as an important 
mechanism in preconditioning cardioprotection. 
Post-conditioning 
Cardioprotection by I-PostC is obtained by short periods of reperfusion intervened by short periods 
of ischaemia (a few seconds) at the beginning of a reperfusion, which follows an infarcting 
ischaemia. Because I-PostC has the advantage that it can be applied after the ischaemic insult has 
occurred, this is therapeutically a more favourable approach than preconditioning. It requires a 
complex signalling cascade to be triggered, which includes the opening of mitoKATP and the 
activation/inhibition of several enzymes of cardioprotective pathways. With regard to signalling 
pathways, also for PostC, as for PreC, the greatest attention has focused on the role of the RISK-, 
the SAFE- and the cGMP/PKG-dependent pathways. Intriguingly, however, I-PostC can be 
completely blocked by free radical large-spectrum scavengers, such as NAC or MPG given during 
I-PostC manoeuvres. However, PostC protection is not abolished if the scavenger is given in 
reperfusion after the PostC manoeuvres have been completed (Downey and Cohen, 2006). More 
intricate is the relationship with more selective antioxidant enzymes, such as SOD and catalase, 
whose activity may be influenced by pH (Penna et al., 2011b; 2013c; Tullio et al., 2013) (see also 
below). Actually, the gradual normalization of intracellular pH in the initial phase of reperfusion 
plays a critical role in conditioning strategies. Both in pre- and in post-conditioning, acidosis 
favours redox signalling and the activation of a complex cascade of signal molecules and prevents 
the opening of mPTP in the early post-ischaemic phase; a phase in which redox signalling plays a 
critical role in triggering cardioprotection (Cohen et al., 2007; 2008; Cohen and Downey, 2011; 
Inserte et al., 2011b; Penna et al., 2011b; 2013a; Tong et al., 2014). In particular, acidosis favours 
the transient formation of S-nitrosylated proteins in post-conditioned hearts (Penna et al., 2011b; 
Tong et al., 2014). NO, nitration and nitrosylation may play a finely interconnected role in post-
conditioning. It is well known that post-conditioning attenuates endothelial cell dysfunction by 
increasing eNOS activity and •NO bioavailability in neighbouring cells (Zhao et al., 2003; Ma et al., 
2006; Granfeldt et al., 2009). This can be responsible for improved vasodilatation in post-
conditioned hearts. Moreover, both pre- and post-conditioning protection can be triggered by 
pharmacological interventions, including the infusion of exogenous •NO donors, that is, 
pharmacological PreC or pharmacological PostC (Valen and Vaage, 2005; Gross and Gross, 2006; 
Jones and Bolli, 2006; Penna et al., 2007; 2008b; Tissier et al., 2007). Indeed, similar to ischaemic 
and pharmacological preconditioning, S-nitrosation/S-nitrosylation is also involved in ischaemic 
and pharmacological post-conditioning. Several studies that used NO donors in reperfusion to 
induce pharmacological PostC revealed an important role for the S-nitrosation/S-nitrosylation of 
proteins in the mechanisms of protection (Nadtochiy et al., 2007; Prime et al., 2009; Methner et al., 
2013). We and Murphy’s group have shown that I-PostC is also mediated by S-nitrosation/S-
nitrosylation of several proteins (Penna et al., 2011b; Tong et al., 2014). Due to the abundance of S-
nitrosylated proteins, it is also likely that denitrosylation processes are down-regulated. In fact, we 
have shown that PostC discretely changes the activity of antioxidant enzymes in early reperfusion, 
slightly decreasing SOD and increasing catalase activity (Penna et al., 2011b; 2013c). Since SOD 
may be a denitrosylating enzyme (Sun and Murphy, 2010), these effects may favour the prevalence 
of S-nitrosothiol proteins, thus reducing injury due to oxidative stress. In fact, it has been proposed 
that the increase in S-nitrosylation could shield critical cysteine residue(s) from further oxidative 
damage upon reperfusion (Tullio et al., 2013; Tong et al., 2014). Importantly, pro-survival enzyme 
activation may depend upon redox-sensitive reactions. For instance, PKC activation can occur via 
S-nitrosative processes (Sun et al., 2006b) and the activation of PKC plays a central role in 
sustaining the cardioprotection induced by post-conditioning (Penna et al., 2006b; Zatta et al., 2006; 
Cohen and Downey, 2011). The S-nitrosation/S-nitrosylation of the mitochondrial F0-F1- ATPase 
described for PreC has also been found in PostC (Tong et al., 2014). This is in line with interesting 
findings reported in a recent study, in which Cys294 of the mitochondrial F0-F1- ATPase was 
found to form a disulfide bond with another cysteine residue in heart failure, whereas the protective 
cardiac resynchronization therapy led to S-nitrosation/Snitrosylation of Cys294 and prevented 
disulfide formation (Wang et al., 2011). It has been found that about 50% of those proteins that 
were S-nitrosylated by PreC were also S-nitrosylated by PostC (Sun et al., 2012; 2013), suggesting 
that there might be a common set of proteins targeted by nitrosative signalling with both PreC and 
PostC. In fact, the S-nitrosation/Snitrosylation processes are not a random reaction but depend upon 
a number of conditions. In fact, the instantaneous redox state and ultrastructural accessibility of 
cysteine residue( s) under low oxygen tension, such as hypoxia, ischaemia and post-conditioning 
intermittent I/R, may determine whether a particular thiol/thiyl radical in a given protein is 
subjected to S-nitrosation/S-nitrosylation (Saini et al., 2004; Foster et al., 2012). During the first 
minutes of reperfusion, usually a typical large burst of ROS occurs in unprotected (naïve) hearts. 
The ROS/RNS burst results in the irreversible oxidation/nitration of a number of important proteins. 
These proteins are damaged and need to be degraded and re-synthesized to regain normal cell 
function; otherwise, irreversible tissue injury occurs. The shielding effect of S-nitrosothiol could be 
necessary to trigger protection in early reperfusion and to allow sufficient time for the activation of 
protective signalling. Since S-nitrosation/S-nitrosylation is a transient readily reversed protein 
modification, timing seems of essence. This could be of extreme importance during I-PostC 
manoeuvres. In fact, the ROS/RNS burst is attenuated (not abolished) by I-PostC manoeuvres, and 
S-nitrosation/S-nitrosylation occurring during post-conditioning may shield modified cysteines 
from more irreversible states of oxidation until the burst of ROS/RNS vanishes. This point of view 
is in line with the experimental evidence that a delay in performing PostC manoeuvres results in a 
loss of protection (Penna et al., 2008a; 2009; Skyschally et al., 2009; Hausenloy, 2013). Actually, it 
has been found that protein nitration may be deleterious in the PostC scenario (Fan et al., 2010; 
Iliodromitis et al., 2010; Inserte et al., 2013). However, other authors have observed a beneficial 
effect for this reaction induced by peroxynitrite (Kupai et al., 2009; Li et al., 2013). We have 
proposed that tyrosine nitration may be a transient initial effect of I-PostC, which is suddenly 
followed by the prevalence of protein S-nitrosylation, possibly via the so-called secondary reaction 
described earlier (Penna et al., 2011b). We have shown in rat hearts that after 7 min of reperfusion, 
I-PostC induces a reduction in the levels of 3-nitrotyrosine formed and a subsequent increase in S-
nitrosylated proteins, which persist for at least 120 min of reperfusion (Penna et al., 2011b). In fact, 
a low level of 3-nitrotyrosine in PostC has often been observed (Kupai et al., 2009; Penna et al., 
2011b; Inserte et al., 2013), but a predominant formation of S-nitrosylated proteins has been 
described (Penna et al., 2011b; Tong et al., 2014). Very recently, we and other authors have shown 
that protein S-nitrosation/Snitrosylation occurs mainly in the mitochondria after I-PostC (Penna et 
al., 2013b; Tong et al., 2014). We have also shown that pharmacological PostC induced by 
diazoxide [a drug supposed to promote ROS signalling through actions on mitoKATP channels and 
connexins (Boengler et al., 2007; 2011; Sánchez et al., 2013)] may induce marked S-nitrosothiol 
formation in the mitochondrial proteins. In another study, the addition of a mitochondria-targeted 
NO donor at the start of reperfusion (i.e. pharmacological PostC) has also been found to be 
cardioprotective (Chouchani et al., 2013). The NO donor used in this study was the so-called 
MitoSNO, which comprises the NO donor S-nitroso-N-acetylpenicillamine conjugated to a 
triphenylphosphonium moiety. This lipophilic moiety allows MitoSNO to pass rapidly through 
membranes driven by the membrane potential and therefore to accumulate several hundred-fold 
within the mitochondria, where it generates •NO and nitrosothiol in proteins (Chouchani et al., 
2013). The S-nitrosation/S-nitrosylation of proteins by MitoSNO and other donors has been 
confirmed by other authors both in basal conditions and in the context of post-conditioning 
cardioprotection (James et al., 2007; Tullio et al., 2013 and references therein). Importantly, S-
nitrosothiol production is a transitory modification, which is reversed by the so-called 
denitrosylation processes (Murphy et al., 2012; 2014; Penna et al., 2014). It is important to 
emphasize that phosphorylative pathways may be activated in parallel or in sequence to the 
nitrosative/nitrosylative processes. For instance, it has been recently reported that the most abundant 
isoform of PKG (PKGI) within cardiomyocytes is involved in cardioprotection against I/R injury. 
However, after cardiomyocytespecific ablation of the PKGI gene in the mouse heart, it was still 
possible to protect the hearts with several interventions, including I-PostC or pharmacological 
PostC with the NO donor MitoSNO, via S-nitrosylation of mitochondrial proteins (Methner et al., 
2013). Therefore, the authors concluded that PostC may afford protection either by bypassing PKGI 
or by acting independently or downstream of it. The authors also suggested differences between 
cGMP/PKGI pathway in myocytes and other cardiac cell types during I-PostC protection in this in 
vivo study. In fact, they cannot rule out that the exogenous and endogenous •NO may act to protect 
the heart from I/R injury in a manner that depends upon PKG in other cardiac cell types (Methner et 
al., 2013). In fact, the PKG pathway has been shown to be involved in PostC protection in different 
models by several authors (Penna et al., 2006a; Inserte et al., 2011a; 2013; Methner et al., 2013). 
In summary, •NO appears to be an important mediator of cardioprotection. In particular, besides its 
well-known vasodilator effects, in pre- and post-conditioning, •NO may be involved in both 
cGMP/PKG-dependent signalling and mitochondrial protein S-nitrosation/S-nitrosylation, thus 
playing a pivotal role in conditioning cardioprotection. Intriguingly, our recent finding that 
diazoxide enhances protein S-nitrosylation both in the absence of ischaemia and in the early post-
ischaemic phase (Penna et al., 2013b) further supports the idea that an appropriate redox 
environment is necessary for NO-mediated cardioprotection induced by both pre- and post-
conditioning. 
Therefore, we can conclude that the oxidative/nitrosative signalling and the increase in S-
nitrosation/S-nitrosylation play pivotal roles in cardioprotection against I/R injury, both 
in pre- and post-conditioning. 
Bench to bedside 
Of course, oxidative stress is an attractive target for novel therapies, as it represents the common 
pathway through which different risk factors exert their deleterious effect on the CVS. Included in 
this spectrum of CVD is AMI. However, we have seen that oxidative steps are necessary for 
cardioprotection. With no doubt, we need more experimental studies to better understand the 
mechanisms of stress-related injury and of redox-dependent protection before having a safe and 
successful transition to clinical scenario of conditioning concepts. The difficulty in obtaining 
positive results with conditioning protocols in humans 
Although the discovery of I-PreC is of paramount importance from a conceptual viewpoint, the 
practical significance of preconditioning is limited by the fact that it is a pretreatment. There is a 
wealth of evidence supporting the notion that the human heart is amenable to preconditioning-
induced protection. Protection can also be obtained with remote conditioning, initiated by ischaemia 
in a remote organ or tissue and transmitted to the heart. However, as AMI is unpredictable, 
preconditioning, whether it is applied to the heart or to a remote organ, is limited to scheduled 
ischaemic events, such as those in patients undergoing cardiac surgery involving cardiac arrest. In 
contrast, post-conditioning, applied either to the heart or to a remote organ, may hold greater 
promise for clinical application. This may be particularly true for ST-segment elevation myocardial 
infarction (STEMI) patients in whom coronary flow is restored via percutaneous coronary 
intervention or thrombolysis. In fact, a few years after the first description of I-PostC protection in 
the canine model by Zhao et al. (2003), Staat et al. (2005) as well as several subsequent phase II 
studies (Yellon and Hausenloy, 2005; Yang et al., 2007; Thibault et al., 2008; Xue et al., 2010; 
Heusch, 2013; Ovize et al., 2013) reported a significant reduction in enzyme release in STEMI 
patients. In these studies, patients were post-conditioned with brief angioplasty balloon 
inflation/deflation immediately after the reopening of the culprit coronary artery and compared with 
controls who underwent standard angioplasty or direct stenting of the coronary artery. More 
recently, however, neutral effects of I-PostC in STEMI patients have been described (Sörensson et 
al., 2010; Freixa et al., 2012; Tarantini et al., 2012; Limalanathan et al., 2014). Thus, data on the 
effects of I-PostC in STEMI treated by primary percutaneous coronary intervention are 
controversial (Laskey, 2005; Laskey et al., 2008; Lønborg et al., 2010; Garcia et al., 2011; Hahn et 
al., 2013). See Table 1 for a summary of results with PostC in humans. In our opinion, it is not 
surprising that a variation (ranging from highly protective to neutral and even negative results) in 
the magnitude of myocardial salvage can be observed among clinical studies. In fact, similar to I/R 
injury, the I-PostC protection may also be influenced by a number of conditions that are not easy to 
keep under the control of the physicians in the ‘clinical arena’. Here, particularly relevant are the 
variables correlated to the duration of ischaemia, the area at risk and the degree/quality of artery 
reopening in controls and I-PostC-treated patients (see Pagliaro et al., 2011; Heusch, 2013; 
Przyklenk, 2013).  
The possibility of triggering post-conditioning by drugs 
Pharmacological PostC would limit the unfavourable consequences linked with the complexity of I-
PostC and provides a simple method of myocardial protection, which can be subsequent to all 
cardiac procedures of artery reopening, including coronary reopening by thrombolysis. Several 
drugs can act as conditioning agents, which reduce the final myocardial infarct size following 
ischaemia–reperfusion (Sivaraman and Yellon, 2014). For some of these, there is some evidence 
supporting the importance of the redox environment, which is the main topic of the present review. 
For instance, much attention has focused on the cardioprotective effects of volatile anaesthetics, 
which are largely shown to be protective in many species, including humans (Huhn et al., 2008; 
Lemoine et al., 2010; Schwiebert et al., 2010). Intriguingly, it has been shown that some of the 
anaesthetic protective effects can be redox-sensitive (Lemoine et al., 2010). Moreover, NO donors 
and molecules that activate protective NO-dependent signalling pathways are promising tools for 
cardioprotection. In particular, organic nitrates and nitrites are effective redox-sensitive 
cardioprotective agents. However, when nitrate tolerance develops, not only do they lose their 
protective effects but they may also interfere with endogenous protective mechanisms by increasing 
nitrative/nitrosative/oxidative stress (Ferdinandy, 2006; Ferdinandy et al., 2007; Zweier et al., 
2010). In this context, a couple of questions arise: (i) is oxidative/ nitrosative signalling in 
cardioprotection a laboratory curiosity, or do these concepts extend to the human heart and clinical 
scenario? (ii) is it better to trigger signalling or to avoid stress? We should consider the complexity 
of these questions and recall to attention the fact that it is not trivial to consider the redox status in 
the context of co-morbidities, mutagenesis, CVD and in particular in I/R injury. Moreover, 
experimental studies that demonstrated the importance of protein S-nitrosation/S-nitrosylation in 
cardioprotective signalling have not yet demonstrated a direct link between the protein 
modifications and cardioprotection. Clearly, however, the approaches aimed simply at avoiding 
stress are not effective.  
The failure of antioxidants 
First of all, let us consider the putative role of antioxidants. The term antioxidant refers to any 
molecule capable of stabilizing or deactivating free radicals and oxidants before they attack cell 
components. It is now clear that large-spectrum antioxidants can abolish conditioning protection. 
Moreover, and more importantly, large clinical trials have failed to demonstrate a benefit of large-
spectrum antioxidants on cardiovascular outcomes (see Table 2). Studies exploring the possibility 
that antioxidants such as vitamin A, C, vitamin E, selenium or folic acid may improve the prognosis 
of patients with CVD have substantially reported neutral and even negative results (Omenn et al., 
1996; Sesso et al., 2008; 2012). In the context of reperfusion, i.v. bolus of either trimetazidine 
(Downey, 1990) or SOD (Flaherty et al., 1994) showed no beneficial effects on the outcome of 
patients. Moreover, p.o. administration of vitamin C (Chen et al., 2013) or the effects of combined 
vitamins C and E, through infusion and capsules (Jaxa-Chamiec et al., 2005; Lee et al., 2005; Cook 
et al., 2007), did not demonstrate a major effect of these antioxidant treatments on the clinical 
outcome of patients. Nevertheless, in diabetic patients, a reduction in 30 day cardiac mortality has 
been reported (Jaxa-Chamiec et al., 2009). Also, in relatively old experimental studies, 
contradictory results were obtained. For example, some have shown that SOD reduces myocardial 
infarct size (Werns et al., 1985), whereas others observed no functional or histological protection 
(Näslund et al., 1992). These contradictory results should suggest a more cautious approach. 
Intriguingly, there are pieces of evidence that the antioxidants may also limit the benefit due to 
exercise. For instance, Ristow et al. (2009) found that the subjects who exercised and did not take 
antioxidant supplements had significant improvements in insulin sensitivity, adiponectin and 
PPAR-coactivator 1, whereas antioxidants inhibited these metabolic benefits of exercise. Exercise 
may be a archetypical example of the benefit from transient oxidative signalling (Copp et al., 2009; 
Ristow and Zarse, 2010; Ristow and Schmeisser, 2011), which also induces an up-regulation of 
eNOS (Lauer et al., 2005). Clearly, indiscriminate removal of oxidative stress by an antioxidant is 
not an effective means to prevent the detrimental processes due to I/R. In fact, oxidative signalling 
is necessary for several physiological functions, including cell survival against I/R and an array of 
noxious stimuli. Therefore, aspecific removal of ROS/RNS with large-spectrum antioxidants cannot 
be considered to achieve clinically meaningful benefit. It seems necessary to consider a site– time-
specific and well-timed inhibition of the source of injurious ROS/RNS without affecting redox-
sensitive survival signal transduction pathways. This may represent a promising approach to elicit 
the beneficial effect of drugs affecting (promoting or inhibiting) ROS/RNS formation. Drugs with 
these characteristics need to be envisaged and studied. However, we can learn something from some 
medications already in use. 
The redox aspects of some effective drugs 
Intriguingly, medications such as ACE inhibitors, angiotensin II receptor blockers or statins, which 
indirectly limit ROS production while favouring •NO production, have been more consistently 
associated with beneficial effects in both preclinical studies and large clinical trials. The redox-
dependent reasons for the success of the therapy with these drugs are not specifically studied. It is 
tempting to speculate that low levels of ROS together with sufficient amount of •NO may favour 
protective processes. As said, site specificity for antioxidant therapy may play a role of paramount 
importance. In fact, ACE inhibitors and angiotensin II receptor blockers may limit (not avoid) ROS 
production by NADPH oxidases. Moreover, ACE inhibitors have the advantage of promoting the 
bioavailability of bradykinin, which, via B2 receptors, induces the release of vasodilator and 
antioxidant substances such as •NO and prostacyclin. In fact, bradykinin has been suggested as a 
conditioning agent in several studies (Penna et al., 2007; 2008b). The data in humans regarding 
bradykinin are more controversial (Wang et al., 2009; Pedersen et al., 2011). Although some 
experimental studies using ACE inhibitors alone have shown cardioprotective effects (Jin and Chen, 
2000; Weidenbach et al., 2000; Penna et al., 2010), others have suggested that ACE inhibitors 
potentiate preconditioning through bradykinin B2 receptor activation, and a further stimulus is 
needed to enhance ACE inhibitors’ protective effects (Morris and Yellon, 1997; Jaberansari et al., 
2001). In the context of PostC, the ACE inhibitor, enalaprilat, has been administered directly into 
the coronary arteries during reperfusion in small clinical trials, with improvement in  inflammation, 
arrhythmias, ST-segment elevation and ventricular repolarization (Bonnemeier et al., 2007; 
Schaefer et al., 2007; Ungi et al., 2008). Of note, there are several large clinical trials showing good 
outcomes with the administration of ACE inhibitors after AMI (Kirkpatrick and St John Sutton, 
2012). Also, statins have been consistently shown to improve the prognosis in patients with 
coronary artery disease, heart failure, hypercholesterolaemia and several other cardiovascular 
conditions. Similar to ACE inhibitors, statins increase •NO bioavailability by means of several 
mechanisms (Lu et al., 2004). Further, statins reverse oxidative stress by decreasing the expression 
and the activity of NADPH oxidase, an effect that overlaps with that described previously for ACE 
inhibitors (Wassmann et al., 2002; Zhou and Liao, 2009).With regard to I/R injury, it has been 
shown that statins reduce infarct size in animal models via RISK- and NO-dependent pathways 
(Bell and Yellon, 2003; Ikeda et al., 2003; Vilahur et al., 2009). Translation to clinical studies has 
been positive in elective or programmed situations where statins may precondition the heart and 
may be beneficial in reducing myocardial injury (Vilahur et al., 2009; Nusca et al., 2010). However, 
the evidence supporting the use of acute high-dose atorvastatin in emergency situations as a post-
conditioning agent is somewhat controversial (Kim et al., 2010; Ludman et al., 2011). To the best of 
our knowledge, there are no large randomized trials using acute high dose of statins in the I/R 
context. Although it is impossible to clearly determine which of the properties 
(antioxidant/pronitrosative, antiproliferative, lipid-lowering effects, haemodynamic, etc.) of these 
drugs is responsible for their therapeutic impact, it is likely that their tenuous antioxidant and •NO 
promoter actions may play a pivotal role. In fact, we have seen how protein redox modifications 
induced by ROS/RNS can regulate and expand protein function under a variety of conditions. While 
irreversible oxidation usually leads to protein aggregation and degradation, reversible nitrosative 
signalling that usually occurs on protein cysteine residues can often serve as a sort of switch that 
regulates protein function and redox signalling pathways upon stress challenges. In the context of 
tolerance against I/R, including pre- and post-conditioning, a wealth of evidence has revealed that 
reversible cysteine redox modifications such as S-nitrosation/S-nitrosylation and S-
glutathionylation formation can serve as a cellular defence mechanism against tissue I/R injury (see 
previous discussion). This is in agreement with our observation that the cardioprotective diazoxide 
induces S-nitrosylation of several proteins either before or after ischaemia (Penna et al., 2013b). In 
the present review, we have highlighted evidence of selective cysteine redox modifications as a 
protective measure in I/R injury, demonstrating that protein redox modifications can serve as a 
therapeutic target for attenuating tissue ischaemic injury. More oxidatively/nitrosatively modified 
proteins and consequent modulation of their function playing protective roles in tissue I/R injury 
need to be identified. In particular, we need to ascertain when and how the oxidatively/ nitrosatively 
modifications of such identified proteins can be enhanced/inhibited by pharmacological agents. 
Based upon the above considerations, therapy with direct antioxidant drugs might have been a naïve 
attempt in a complex pathophysiology. Definitely, we need more mechanistic studies to characterize 
better the sequences of events leading from ROS/RNS to cardiovascular damage or alternatively to 
cardiovascular protection, and whether there are particular components of these sequences that can 
be specifically targeted pharmacologically by agents that are available or need to be developed. It is 
likely that research efforts need to be redirected towards a redox-oriented approach.We know that 
the redox environment may be profoundly influenced by concomitant diseases and it is likely that 
each patient may have a different metabolic background in which I/R may trigger a different redox 
response. Therefore, it is likely that a personalized therapy is necessary to obtain beneficial effects 
and to redirect the redox response to beneficial rather than deleterious effects.  
 
Summary and conclusions 
A plethora of evidence collected throughout the past three decades has shown that ischaemic 
conditioning, including preconditioning, post-conditioning and remote conditioning, elicits 
endogenous cardiac protection. There is no doubt that the heart may be redirected to be less 
vulnerable to I/R injury and that, in this ‘redirection’, a role of paramount importance is played by 
redox signalling. However, translation of pre- and post-conditioning into clinical protocols is still in 
its infancy. In our opinion, such translation is, in part, impaired by the complex and intricate role of 
redox stress and redox signalling in cardiac injury and protection respectively. Here, too, a picture is 
emerging that induces us to rethink our beliefs: the reactive species are not always good or always 
bad and also in reperfusion they may play a beneficial role. Clinical application of ischaemic or 
pharmacological conditioning will depend, at least in part, upon enhancing our understanding of 
mechanistic and physiological components of redoxdependent myocardial injury and protection. Of 
course, technical complications in the reperfusion strategies and confounding effects of co-
morbidities on the cardiovascular phenotype cannot be ignored and must be taken into consideration 
to maximize the beneficial effects of reperfusion.  
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Table 1 
Outcome of clinical studies that used I-PostC  
Study Protocola Patients No. Results 
Staat et al. (2005) 4 × 60 s 30 Positive 
Laskey (2005) 2 × 90 s 17 Positive 
Ma et al. (2006) 3 × 30 s 94 Positive 
Yang et al. (2007) 3 × 30 s 41 Positive 
Thibault et al. (2008) 4 × 60 s 38 Positive 
Laskey et al. (2008) 2 × 90 s 24 Positive 
Lønborg et al. (2010) 4 × 30 s 118 Positive 
Sörensson et al. (2010) 4 × 60 s 76 Positive 
Xue et al. (2010) 4 × 60 s 43 Positive 
Lin et al. (2010) 3 × 60 s 75 Positive 
Garcia et al. (2011) 4 × 30 s 43 Positive 
Hahn et al. (2013) 4 × 60 s 700 No differences 
Limalanathan et al.(2014) 4 × 60 s 272 No differences 
aCycles × Duration of each cycle of ischaemia and reperfusion. 
 
 
 
Table 2 
Clinical trials investigating the effect of antioxidants on CVD 
Treatment Patients No. Result Ref. 
β-Carotene 39 876 No benefit Hennekens et al. (1996) 
Vitamin A+ β-carotene 14 641 No benefit Omenn et al. (1996) 
Vitamin E 22 071 No benefit Lee et al. (2005) 
Vitamin C + E + β-carotene 73 135 No benefit Cook et al. (2007) 
Vitamin C + E 8171 No benefit Sesso et al. (2008) 
Vitamin B6 + B12 + folic acid 6837 No benefit Ebbing et al. (2010) 
Multivitamin 14 641 No benefit Sesso et al. (2012) 
Vitamin C Meta-analysis Adverse effects Chen et al. (2013) 
 
 
 
 Figure 1 
Reactive oxygen and nitrogen species (ROS/RNS) have been identified as a part of cardioprotective 
signalling molecules, which are essential in pre- and post-conditioning processes. S-
nitrosation/Snitrosylation of enzymes is a specific posttranslational modification that plays an 
important role in cardioprotection. Mitochondria are of paramount importance in either promoting 
or limiting ROS/RNS generation and reperfusion injury, and in triggering kinase activation by 
ROS/RNS signalling in cardioprotection. Ade, adenosine; BK, bradykinin. For other acronyms, see 
the abbreviation list.  
 
 
 
Figure 2 
Chemical relationship among reactive oxygen species (ROS) and different reactive nitrogen species 
(RNS), which can lead to nitrosylation or to nitration. Nitrosylation/Nitrosation refers to the 
incorporation of the NO moiety (nitroso/nitrosyl group) to a metal and, in protein chemistry, to a 
sulfur atom to form the S–NO bond (SNO): S-nitrosothiol. Nitration is a term that describes 
incorporation of a nitro triatomic group (–NO2) and which, in protein chemistry, is used to describe 
the incorporation of that group at position 3 of the phenolic ring of tyrosine residues (3-NT). ROS 
chemistry is simplified in the scheme by O2− formation. For other acronyms, see the abbreviation 
list. 
 Figure 3 
Several interlinked reactions that involve mitochondria respiration, xanthine oxidase, NADPH 
oxidases, and coupled and uncoupled NOS, which are associated with the production of reactive 
oxygen and nitrogen species (ROS/RNS) within cells under pathophysiological conditions. The rate 
of mitochondrial respiration and ROS formation is largely influenced by the internal and external 
Ca2+ levels and antioxidant activity within mitochondria [i.e. superoxide dismutase (SOD)], and, in 
turn, by factors such as RIRR. Also, the shift from coupled to uncoupled NOS and the production of 
ROS by XO are influenced by the levels of ROS/RNS. The dotted arrows indicate this possibility to 
influence the activity of these enzymes and to sustain the so-called ROS-induced ROS production.  
 
 
 
